Publications

• Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

  J. Roeper, S. Kurz, C. Grohé, F. Griesinger

  PMID: 33094641 Show Details link to full text
  Study

  Year

  2021

  Keywords

  • EGFR
  • NSCLC
  • tyrosine kinase inhibitor
  • oncology

• Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial

  L. Zimmer, A. Krackhardt, E. S. Schultz, D. Goeppner, C. Assaf, D. Trebing, E. Livingstone, D. Schadendorf

  PMID: Show Details link to full text
  Study

  IMMU-Target

  Year

  2021

  Keywords

  • pembrolizumab
  • encorafenib
  • binimetinib
  • oncology
  • BRAF mutation

• A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer

  M. Hecht, D. Hahn, P. Wolber, M. G. Hautmann, D. Reichert, S. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, C. Große-Thie, O. Guntinas-Lichius, J. von der Grün, P. Balermpas, K. Orlowski, D. Messinger, K. G. Stenzel, R. Fietkau

  PMID: 34298628 Show Details link to full text
  Study

  SOCCER

  Year

  2021

  Keywords

  • cetuximab
  • head and neck cancer
  • oncology

• Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

  BEAMing, circulating tumor DNA, clonal selection, colorectal cancer, digital droplet PCR, liquid biopsy, methylation WIF1 promotor, neoRAS wild-type

  PMID: 32766143 Show Details link to full text
  Study

  RAS Convert VP

  Year

  2020

  Keywords

  • colorectal cancer
  • liquid biopsy
  • neoRAS wild-type
  • oncology

• Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.

  U. Nestle, T. Schimek-Jasch, S. Kremp, A. Schaefer-Schuler, M. Mix, A. Küsters, M. Tosch, T. Hehr, S. M. Eschmann, Y. P. Bultel, P. Hass, J. Fleckenstein, A. Thieme, M. Stockinger, K. Dieckmann, M. Miederer, G. Holl, H. C. Rischk, E. Gkika, S. Adebahr, J. König, A. L. Grosu

  PMID: 32171429 Show Details link to full text
  Study

  PET Plan

  Year

  2020

  Keywords

  • radiotherapy
  • NSCLC
  • PET/CT
  • oncology

• Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results

  N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger

  PMID: 32550760 Show Details link to full text
  Study

  Go CUTE I

  Year

  2020

  Keywords

  • ulcerative colitis
  • QoL
  • golimumab

• Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany

  ankylosing spondylitis, golimumab, patient-reported outcome measures, psoriatic arthritis, rheumatoid arthritis

  PMID: 32722921 Show Details link to full text
  Study

  GO-ARTeXTRA

  Year

  2020

  Keywords

  • ankylosing spondylitis
  • golimumab
  • psoriatic arthritis
  • rheumatoid arthritis

• Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance

  C. Jackisch, R. Kreienberg, M. Blettner, N. Harbeck, H. J. Lück, R. Haidinger, D. C. Schmitt, H. Schulte, C. Windemuth-Kieselbach, S. Zaun, P. Hadji

  PMID: 32774217 Show Details link to full text
  Study

  PACT Trial

  Year

  2020

  Keywords

  • aromatase inhibitors
  • breast cancer
  • oncology

• Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration

  A. Ebneter, S. Michels, C. Pruente, P. Imesch, F. Eilenberger, S. Oesch, I. P. Thomet-Hunziker, K. Hatz

  PMID: 33219242 Show Details link to full text
  Study

  Asteria

  Year

  2020

  Keywords

  • nAMD
  • aflibercept

• Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

  L. Zimmer, E. Livingstone, J. C. Hassel, M. Fluck, T. Eigentler, C. Loquai, S. Haferkamp, R. Gutzmer, F. Meier, P. Mohr, A. Hauschild, B. Schilling, C. Menzer, F. Kieker, E. Dippel, A. Rösch, J. C. Simon, B. Conrad, S. Körner, C. Windemuth-Kieselbach, L. Schwarz, C. Garbe, J. C. Becker, D. Schadendorf; Dermatologic Cooperative Oncology Group

  PMID: 32416781 Show Details link to full text
  Study

  IMMUNED

  Year

  2020

  Keywords

  • melanoma
  • ipilimumab
  • nivolumab
  • oncology